HC Wainwright & Co. Reiterates Buy on Oncternal Therapeutics, Maintains $19 Price Target

Benzinga · 05/31 10:12
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Oncternal Therapeutics (NASDAQ:ONCT) with a Buy and maintains $19 price target.